Ocugen preps dry eye disease drug for phase 3 by Phil Taylor Tuesday, March 20, 2018 Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.
Aeterna review, Allegro eye test and Ocugen orphan tag—News of Note by Ben Adams Wednesday, August 9, 2017 Here's Wednesday's prescription for your biopharma news of note.
Chutes & Ladders—BIO elects John Maraganore as new chair by Angus Liu Thursday, June 22, 2017 BIO elected Alnylam CEO Maraganore as new chair, Neon tapped ex-Merrimack CFO Al-Wakeel, Biogen hired ex-Shire exec Gregory to lead human resources.
Eye specialist Ocugen looks east for second-round fundraising by Phil Taylor Thursday, June 15, 2017 Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials.
